Medical therapy for benign prostatic hyperplasia progression

Current Urology Reports

Volumn 3, Issue 4, 2002, Pages 269-275

  McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute Urinary Retention; Benign Prostatic Hyperplasia; Doxazosin; Finasteride; Tamsulosin

Indexed keywords

ANTIANDROGEN;

DISEASE COURSE; HUMAN; MALE; MICTURITION DISORDER; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; REVIEW; URODYNAMICS;

ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC HYPERPLASIA; URINATION DISORDERS; URODYNAMICS;

EID: 0036674918     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-002-0047-y     Document Type: Article

References (48)

1. Berry SJ, Coffey DS, Walsh PC, et al.: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474–489.
2. Robson MC: The incidence of benign prostatic hyperplasia and prostatic carcinoma in cirrhosis of the liver. J Urol 1964, 92:307–310.
3. Lytton B: Interracial incidence of benign prostatic hypertrophy. In Benign Prostatic Hypertrophy. Edited by Hinman F. New York, Springer-Verlag; 1983:22–26.
4. Grayhack JT: Benign prostatic hyperplasia: the scope of the problem. Cancer 1992, 70:275–279. DOI: 10.1002/1097-0142(19920701)70:1+<275::AID-CNCR2820701314>3.0.CO;2-3
5. Guess HM, Arrighi HM, Metter EJ, et al.: Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990, 17:241–246. DOI: 10.1002/pros.2990170308
6. Glynn RJ, Campion EW, Bouchard GR, et al.: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985, 121:78–90.
7. Chute CG, Panser LA, Girman CJ, et al.: The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993, 150:85–89.
8. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991, 338:469–471. DOI: 10.1016/0140-6736(91)90543-X
9. Tsukamoto T, Kumamoto Y, Masumori N, et al.: Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995, 154:402–403. DOI: 10.1016/S0022-5347(01)67059-9
10. Arrighi HM, Guess HA, Metter EJ, et al.: Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990, 16:253–261. DOI: 10.1002/pros.2990160309
11. Chai TC, Belville WD, McGuire EJ, et al.: Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993, 150:1710–1713.
12. Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. In Prostate Diseases. Edited by Lepor H, Lawson RK. Philadelphia: WB Saunders; 1993:96–107.
13. Barry MJ, Cockett AT, Holtgrewe HL, et al.: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993, 150:351–358.
14. Guess HM: Natural history of benign prostatic hyperplasia. In Alternate Methods in the Treatment of Benign Prostatic Hyperplasia. Edited by Romas NA, Vaughn ED. Berlin: Springer-Verlag; 1993:1–12.
15. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185–1191. DOI: 10.1056/NEJM199210223271701
16. McConnell JD, Barry MS, Bruskewitz RC, et al.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline no 8. Rockville, MD: Department of Health and Human Services; 1994.
17. McConnell JD: The impact of medical therapy on the progression of BPH: results from the MTOPS Trial [abstract 1042]. Paper presented at the American Urological Association Annual Meeting. Orlando, FL. May 28, 2002.
18. Girman CJ, Panser LA, Chute CG, et al.: Natural history of prostatism: urinary flow rates in a community-based study. J Urol 1993, 150:887–892.
19. Ball AJ, Feneley RC, Abrams PH: The natural history of untreated “prostatism.” Br J Urol 1981, 53:613–616.
20. Birkhoff JD: Natural history of benign prostatic hypertrophy. In Benign Prostatic Hypertrophy. Edited by Hinman F. New York: Springer-Verlag; 1983:5–9.
21. Chancellor MB, Rivas DA: American Urological Association Symptom Index for women with voiding symptoms: lack of index specificity for benign prostatic hyperplasia. J Urol 1993, 150:1706–1708.
22. Jacobsen SJ, Jacobson DJ, Girman CJ, et al.: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997, 158:481–487. DOI: 10.1016/S0022-5347(01)64508-7
23. McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998, 338:557–563. This report details the results of the important PLESS Trial. Long-term treatment with finasteride was demonstrated to impact the rate of AUR occurrence and need for surgery. DOI: 10.1056/NEJM199802263380901
24. Taube M, Gajraj H: Trial without catheter following acute retention of urine. Br J Urol 1989, 63:180–182.
25. Sarmina I, Resnick MI: Obstructive uropathy in patients with benign prostatic hyperplasia. J Urol 1989, 141:866–869.
26. George NJ, Feneley RC, Roberts JB: Identification of the poor risk patient with prostatism and detrusor failure. Br J Urol 1986, 58:290–295.
27. Jones DA, Gilpin SA, Holden D, et al.: Relationship between bladder morphology and long-term outcome of treatment in patients with high pressure chronic retention of urine. Br J Urol 1991, 67:280–285. DOI: 10.1111/j.1464-410X.1991.tb15135.x
28. Flanigan RC, Reda DJ, Wasson JH, et al.: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative study. J Urol 1998, 160:12–16. DOI: 10.1016/S0022-5347(01)63011-8
29. Lytton B, Emery JM, Harvard BW: The incidence of benign prostatic obstruction. J Urol 1968, 99:639–645.
30. Swyer GI: Post-natal growth changes in the human prostate. J Anat 1944, 78:130–145.
31. Huggins CJ, Stevens RA: Effect of castration on BPH of the prostate of men. J Urol 1940, 43:705–714.
32. Schroeder FH, Westerhof M, Bosch RJ, et al.: Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. Eur Urol 1986, 12:318–321.
33. Wendel E, Brannen GE, Putong PB, Grayhack JT: The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J Urol 1972, 108:116–119.
34. Norman RW, Coakes KE, Wright AS, Riggmaster RS: Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993, 150:1736–1739.
35. Bruskewitz R, Girman CJ, Fowler J, et al.: Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999, 54:670–678. DOI: 10.1016/S0090-4295(99)00209-5
36. Roehrborn CG, McConnell JD, Lieber M, et al.: Serum prostatespecific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999, 53:473–480. This manuscript is valuable because it identifies the predictive capability of PSA as a surrogate for prostate size in the stratification of risk for BPH progression. DOI: 10.1016/S0090-4295(98)00654-2
37. Lepor H, Dixon C, Crawford DE, et al.: A randomized double blind placebo controlled phase II study of the safety and efficacy of Cetrorelix in men with BPH. Paper presented at the American Urological Association Annual Meeting. New Orleans, LA. April 1997.
38. Lepor H, Williford WO, Barry MJ, et al.: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998, 160:1358–1367. The effect of combination therapy noted in the MTOPS trial appears to be at odds with the VA Cooperative Trial in which terazosin and finasteride in combination did not appear to add benefit to terazosin monotherapy. It should be remembered that the VA study was of short duration (1 year) and only measured alterations in symptoms, while the MTOPS Trial was a longer (4-year) evaluation of overall BPH progression. DOI: 10.1016/S0022-5347(01)62536-9
39. Lepor H: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998, 51:901–906. DOI: 10.1016/S0090-4295(98)00127-7
40. Caine M, Pfau A, Perlberg S: The use of α-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976, 48:255–263.
41. Lepor H, Knapp-Maloney G, Sunshine H: A dose titration study evaluating terazosin, a selective, once-a-day α 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1990, 144:1393–1397.
42. Roehrborn CG, Oesterling JE, Auerbach S, et al.: The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996, 47:159–168. DOI: 10.1016/S0090-4295(99)80409-9
43. Chapple CR: Selective α-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Euro Urol 1996, 29:129–144.
44. Fawzy A, Braun K, Lewis GP, et al.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995, 154:105–109. DOI: 10.1016/S0022-5347(01)67240-9
45. Gillenwater JY, Conn RL, Chrysant SG, et al.: Doxazosin for the treatment of benign prostatic hyperplasia in mild to moderate essential hypertension: a double-blind, placebocontrolled, dose-response multicenter study. J Urol 1995, 154:110–115. DOI: 10.1016/S0022-5347(01)67243-4
46. Narayan P, Tewari A: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998, 160:1701–1706. DOI: 10.1016/S0022-5347(01)62386-3
47. Lepor H: Adrenergic blockers for the treatment of benign prostatic hyperplasia in prostatic diseases. In Prostate Diseases. Edited by Lepor H, Lawson RK. Philadelphia: WB Saunders; 1993:297–307.
48. Steers WD, Albo M, Tuttle JB: Calcium channel antagonists prevent urinary bladder growth and neuroplasticity following mechanical stress. Am J Physiol 1994, 266:R20-R26.